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Abstract
Within the last decade, a broad range of biomarkers associated with an increased risk
for death and cardiovascular/cerebrovascular endpoints have been identified. Epide‐
miological studies clearly indicate that lipoprotein-associated phospholipase A2 (Lp-
PLA2) has the potential to become clinically useful emerging biomarker in the true
sense, linking plaque biology with cardiovascular/cerebrovascular event rate. Lipo‐
protein-associated phospholipase A2 is a specific vascular inflammatory marker, a risk
factor, a prognostic biomarker, and also a therapeutic target. This chapter will sum‐
marize our current knowledge on Lp-PLA2 with emphasis on its potential pathophy‐
siological mechanisms of action and on clinical relevance as cardiovascular/
cerebrovascular biomarker. This chapter gives comprehensive, systematic review of
studies assessing the significance of Lp-PLA2 in cardiovascular/cerebrovascular dis‐
eases with emphasis on clinical benefit of pharmacologic inhibition of Lp-PLA2.
Keywords: biomarker, cardiovascular disease, lipoprotein-associated phospholipase
A2
1. Introduction
Although an atherogenic lipoprotein phenotype was reported as a predictor of cardiovascular/
cerebrovascular disease, numerous recent studies have recognized additional lipid-related
markers as emerging biomarkers to identify patients with cardiovascular/cerebrovascular
disease risk. Among them the most promising biomarkers for cardiovascular/cerebrovascular
risk assessment is lipoprotein-associated phospholipase A2 (Lp-PLA2).
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Lipoprotein-associated phospholipase A2: structure and biology
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor
acetylhydrolase (PAF-AH), belongs to the phospholipase A2 superfamily [1,2]. This Ca2+-
independent phospholipase is encoded by PLA2G7 gene that consists of 12 exons and 11 introns
located on chromosome 6p21.2 to 12 [3,4]. Lp-PLA2 is protein of 45,4 kDa that consists of 441
amino acid residues [5]. The major sources of Lp-PLA2 in plasma are T lymphocytes, mono‐
cytes/macrophages, activated bone marrow-derived mast cells, and liver cells [6-8]. The
secreted Lp-PLA2, circulates in plasma in active form. It predominantly binds to LDLs, and in
a much smaller extent to HDLs, Lp(a), lipoprotein remnants, and platelet-borne microparticles
[6,9-12]. Indeed, Lp-PLA2 is highly associated with the smallest LDL and HDL subclasses [13]
and with electronegative LDL, which overlaps with small dense LDL [14]. Lp-PLA2 bound to
HDL has a much lower specific activity compared to when bound to LDL [10]. Different
distribution of Lp-PLA2 in various plasma lipoproteins affects its functions.
Lp-PLA2 catalyzes hydrolysis of the acetyl group at sn-2 position of PAF to generate lyso-PAF
and acetate [15]. On the other side, Lp-PLA2 cleaves oxidatively modified lipoproteins from
the sn-2 position of the apoB100-containing lipoproteins into oxidized nonesterified fatty acids
(oxFFAs) and lysophosphatidylcholine.
3. Actions of lipoprotein-associated phospholipase A2
We can think about Lp-PLA2 as a friend and foe at the same time. On the one hand, it functions
as PAF-AH, which hydrolyzes inflammatory mediator PAF, inhibits foam cell formation,
enhances cholesterol efflux in macrophages, and exerts its atheroprotective role [16].
On the other hand, Lp-PLA2 has a proatherogenic role. Lp-PLA2 relates to a number of different
proatherogenic biological processes. Lp-PLA2 hydrolyzes oxidized phospholipids on modified
LDL particles within the arterial intima, and thus contributes to the initiation and progression
of atheroma. Lp-PLA2 is produced by macrophages and foam cells within atherosclerotic
plaque. Its expression is mainly confined to plaque areas with massive lipid accumulation and
leukocyte infiltration, cellular necrosis, and calcification, suggesting that Lp-PLA2 is a marker
for rupture-prone plaque [16]. The amount of Lp-PLA2 and its by-product, lysophosphatidyl‐
choline in the coronary circulation is proportional to the extent of the atheroma and indirectly
affects local endothelial function [17]. Proatherogenic activities of lysophosphatidylcholine
are: expression of adhesion molecules; upregulation of cytokines and CD40 ligand by T-cells,
cytotoxic at concentrations higher than 30–50 μM; stimulation of macrophage proliferation;
release of arachidonic acid from endothelial cells; induction of MCP-1 and genes for growth
factors; release of myeloperoxidase; migration of vascular smooth muscle cells; chemoattrac‐
tant for monocytes, macrophages, and T-cells; induction of apoptosis in smooth muscle cells
and macrophages; involvement in the antigenicity of oxidized LDL; inhibition of endothelium-
derived nitric oxide [18-20]. Furthermore, oxFFAs promote atherosclerosis by direct and
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indirect increasing of oxidative stress and the presence of oxidized LDL and other lipoproteins
in the plasma and arterial walls, thereby initiating fatty streak formation [21].
4. Assays for Lp-PLA2 mass and activity determination
It is well known that circulating Lp-PLA2 can be measured by different assays ascertaining
either its mass or activity. There is no definite decision about the potential superiority of the
tests.
According to the literature data, Lp-PLA2 levels were determined preferentially using PLAC®
test. Lp-PLA2 mass was determined by diaDexus PLAC Test ELISA, sandwich enzyme
immunoassay, followed by diaDexus PLAC® test based for Lp-PLA2 mass measurement on
turbidimetric immunoassay technology. More recently, enzyme assay PLAC® Test for
measurement of Lp-PLA2 activity has been developed and commercially available. The
preferred sample type is EDTA plasma, and serum is also acceptable. It should be noted that
methodological issues associated with Lp-PLA2 measurement make comparisons between
studies difficult.
Recently published meta-analysis of 32 prospective studies in persons with stable vascular
disease or recent acute ischemic event revealed a moderate correlation between mass and
activity of Lp-PLA2 [24]. The PROVEIT-TIMI 22 study [25] has also found a moderate corre‐
lation between Lp-PLA2 activity and mass measured at baseline and at 30-day after ACS. There
is still controversy about the method of estimating Lp-PLA2 level. While Koenig et al. [26]
reported that Lp-PLA2 mass was the better risk predictor of future cardiovascular events than
Lp-PLA2 activity, Persson et al. [27] has reached the opposite conclusion. Jenny et al. [28]
showed no difference in Lp-PLA2 activity and mass with respect to risk prediction.
Currently, there is no consensus on the best method to estimate Lp-PLA2 level. A consensus
panel recommendation for incorporating Lp-PLA2 testing into the cardiovascular disease risk
assessment guidelines used Lp-PLA2 mass for stratifying patients [23].
Blood samples should be refrigerated after processing and should be kept frozen for long-term
storage. There are no restrictions to the time of day that the sample should be drawn and no
dietary restrictions. In contrast to other emerging risk markers, a very minimal biological
variation in Lp-PLA2 concentrations has been demonstrated among individuals monitored
serially over several weeks [29].
In addition, Lp-PLA2 levels are typically unaffected by conditions of systemic inflammation,
such as osteoarthritis and chronic obstructive pulmonary disease, whereas markers of
inflammatory response are often elevated by these conditions. The normal population medians
for men and women are in the range of 230–250 ng/mL, and a value of >300 ng/mL may be
considered elevated [30].
Gender differences in Lp-PLA2 levels were found; men had significantly higher levels than
women. Also, a significant association between Lp-PLA2 levels and smoking was noticed.
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These finding has been observed in previous studies [31,32,33,34]. Lower Lp-PLA2 levels in
women could be explained by estrogen-mediated down-regulation of Lp-PLA2 expression,
due to lower concentrations of LDL cholesterol in women or estrogen-related decrease in
platelet activating factor acetyl hydrolase activity [35,36]. Estrogen-replacement therapy can
significantly reduce Lp-PLA2 activity in healthy postmenopausal women [37], while admin‐
istration of steroids with progesterone-like activity increases Lp-PLA2 activity [38]. Smoking
may increase the carrier (LDL) and the substrate (oxidized LDL) for Lp-PLA2 [39].
5. Association of Lp-PLA2 with cardiovascular disease risk
Lp-PLA2 is an emerging inflammatory biomarker, characterized by high vascular specificity
and low biovariability. High Lp-PLA2 levels are indicative of rupture-prone plaque [22].
Numerous epidemiological and clinical studies examined association between Lp-PLA2
concentration/enzyme activity and cardiovascular disease risk in apparently healthy individ‐
uals, in subjects with stable cardiovascular disease, acute coronary syndrome (ACS), heart
failure (HF), stroke, transient ischemic attack (TIA) support, trying to answer in which patients
would determination of Lp-PLA2 be the most valuable. There are novel data about the
prognostic significance of Lp-PLA2 as a predictor of short-term or long-term outcome in
patients with cardiovascular disease. To evaluate this, systematic literature review concerning
the association of Lp-PLA2 with cardiovascular disease risk and prognostic implications was
done. The studies on this issue were extracted from relevant electronic databases (Medline
(http://www.ncbi.nlm.nih. gov/pubmed/), Embase (http://www. embase.com/), Google
Scholar (http://scholar. google.com/), Yahoo (http:// www. yahoo. com/), Kobson (http://
www.kobson.nb.rs/), ClinicalTrails.gov.) and the obtained results were included in the text.
In 2008, the panel’s recommendation [23] incorporated Lp-PLA2 testing as an adjunct to
traditional risk factors in assessing future cardiovascular risks. It endorses Lp-PLA2 testing in
moderate-risk persons determined as having simply two risk factors. An Lp-PLA2 >200 ng/mL
warrants reclassification of the moderate-risk patient as high cardiovascular risk and should
prompt reduction of the LDL-C target from 130 mg/dL to 100 mg/dL. The panel also recom‐
mends Lp-PLA2 testing for patients with coronary artery disease (CAD) or CAD risk equiva‐
lents (diabetes, ischemic stroke, etc.) be considered at very high risk when Lp-PLA2 is elevated,
warranting reduction in the LDL-C target from 100 mg/dL to 70 mg/dL. Today, Lp-PLA2
measurement for cardiovascular disease risk stratification of patients is included in four
international clinical guidelines: 2012 European Guidelines on CVD Prevention in Clinical
Practice European Society of Cardiology – Lp-PLA2 may be measured as a part of a refined
risk assessment in patients at high risk of a recurrent acute atherothrombotic event. Class IIb;
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
– Lp-PLA2 testing may be considered in intermediate-risk asymptomatic adults; 2011
AHA/ASA Guidelines for the Primary Prevention of Stroke Measurement of inflammatory
markers such as high sensitive C-reactive protein (hs-CRP) or Lp-PLA2 in patients without
CVD may be considered to identify patients who may be at increased risk of stroke; 2012 AACE
Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis Test for Lp-
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PLA2, which in some studies has demonstrated more specificity than highly sensitive CRP,
when it is necessary to further stratify a patient’s CVD risk [40-43].
Some studies suggested that Lp-PLA2 predicts risk complementary to hs-CRP, although when
compared with hs-CRP, Lp-PLA2 in some studies is suggested to be a more promising marker
of risk prediction. In multiple previous studies, correlation analysis revealed no association of
Lp-PLA2 with CRP [28,31,44-47]. It can be expected because CRP is an acute-phase reactant
and its elevation can be caused by a wide range of inflammatory conditions. CRP shows
intraindividual variability of ∼40%. On the other hand, Lp-PLA2 is not affected by systemic
inflammation; it is a specific marker of vascular inflammation. Also, it shows significantly
lower biologic variability than CRP, and higher stability in states of myocardial ischemia [48].
Lp-PLA2 is suggested to be a more promising marker of risk prediction than CRP [49]. Winkler
et al. [50] showed that increased Lp-PLA2 levels in moderate-risk patients with hs-CRP<3 mg/
L doubled the risk for cardiac death. The WOSCOPS study [44] found that Lp-PLA2 was
significantly associated with cardiovascular risk, compared with hs-CRP. Stankovic et al.’s [32]
results confirmed that Lp-PLA2 have better risk prediction than CRP.
Although, the majority of published studies showed a significant relationship between Lp-
PLA2 levels and cardiovascular events, there are several important differences across ethnic
groups; for example, African-Americans and Caucasians with respect to Lp-PLA2. Activity of
Lp-PLA2 was higher among African-Americans with CAD. The difference in Lp-PLA2 activity
levels between CAD and non-CAD patients was higher among African-Americans. Also, the
Lp-PLA2 index was independently associated with the extent of CAD among African-
Americans [51-53].
From the WOSCOPS publication (West of Scotland Coronary Prevention Study, WOSCOPS)
[44], which revealed a positive association between elevated circulating concentrations of Lp-
PLA2 and the risk of coronary heart disease (CHD), the interest in Lp-PLA2 as a biomarker for
cardiovascular disease rapidly increased. The vast body of evidence derived from prospective
epidemiologic studies, two meta-analyses (79,036 participants in 32 prospective studies, and
52,995 subjects participated in 33 studies) and review revealed the positive association of
elevated Lp-PLA2 with cardiovascular risk [24,54-56]. Furthermore, Lp-PLA2 has been
confirmed to predict the presence of CAD, even among patients undergoing coronary
angiography. Uniquely, Lp-PLA2 predicted the risk of CAD death, but not all cause death [57].
LpPLA2 has been considered as a prognostic marker in patients with CAD. Li et al. [58]
identified prognostic value of Lp-PLA2 baseline measurement for major adverse cardiac event
(MACE) (cardiovascular death, nonfatal myocardial infarction, and target vessel revasculari‐
zation) in ACS patients during follow-up for a median of 6 months. Mockel et al. [59] demon‐
strated that Lp-PLA2 levels in the first 7 hours after onset of symptoms may be an independent
predictor of MACE within 42 days in ACS patients. PROVEIT-TIMI 22 study [25] has shown
that Lp-PLA2 in patients randomized to atorvastatin or pravastatin measured 30 days after
ACS are associated with an increased risk of cardiovascular events (death, myocardial
infarction, unstable angina, revascularization, or stroke) over 24 months of follow-up. Gerber
et al. MACE [48] found that Lp-PLA2 level measured early after myocardial infarction is
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strongly and independently associated with 1-year mortality. Stankovic et al. [32] demon‐
strated that the Lp-PLA2 may have short-term predictive value in pure STEMI patients treated
by primary percutaneous coronary intervention (PCI). They concluded that pre-interventional
plasma Lp-PLA2 level is an independent predictor of 30-day MACE in patients with first
anterior STEMI treated by primary PCI, and suggested that Lp-PLA2 level could help in very
early risk stratification of STEMI patients treated by PCI.
Previously published studies examined and suggested the association between Lp-PLA2 and
heart failure (HF) incidence in a population-based cohort of healthy individuals, and in people
older than 65 years [60]. Baseline Lp-PLA2 levels are associated with a high risk of developing
heart failure in 3,991 adults older than 65 years, independent of coronary risk factors [61]. Lp-
PLA2 activity is significantly associated with congestive heart failure in 5,531 persons older
than 65 years [62]. Gerber et al. [63] evaluated the association of Lp-PLA2 with mortality in
subjects with diagnosed HF. Lp-PLA2 was strongly and independently associated with
mortality in patients under 80 years of age. Moldoveanu et al.’s study [64] in 208 patients with
HF found significantly increased Lp-PLA2 activity in HF patients with preserved ejection
fraction (EF) than in HF with reduced EF. The literature data about the association of Lp-
PLA2 and heart failure on admission in patients with acute myocardial infarction are missing.
Stankovic et al. [32] suggested that patients with the first anterior STEMI who had higher levels
of Lp-PLA2 had a worse prognosis, but not with a greater probability of developing HF. In
Raichlin et al.’s [65] study in heart transplant patients, Lp-PLA2 correlated with the progression
of cardiac allograft vasculopathy and increased risk of cardiovascular events/death suggesting
that it could be therapeutic target in heart transplant patients.
In 2005, the US Food and Drug Administration (FDA) approved Lp-PLA2 blood test for
assessing patients at risk for ischemic stroke. The Rotterdam Study was the first population-
based study that determined the impact of elevated Lp-PLA2 on stroke. It identified that Lp-
PLA2 activity was an independent predictor of ischemic stroke in the middle-aged healthy men
and women population [31]. In the ARIC study, healthy middle-aged adults with increased
levels of both Lp-PLA2 and hs-CRP had an 11-fold higher incidence of stroke than individuals
with low Lp-PLA2 and hs-CRP levels [45]. This association between Lp-PLA2 mass/activity and
first ischemic stroke was confirmed in the Malmo Diet and Cancer Study [66], Bruneck Study
[67], and Cardiovascular Health Study [28]. The Tsekepis et al. study [68] showed that Lp-
PLA2 correlated with the intima-media thickness in patients with beta-thalassemia, suggesting
that Lp-PLA2 may be implicated in premature carotid atherosclerosis.
Although some reports inconclusively found this positive association of Lp-PLA2 and first-
ever and recurrent stroke, little is known about its influence on stroke outcome. Elkind et al.
[69] measured Lp-PLA2 mass and activity in relation to outcome in first ischemic stroke
patients, determined as recurrent stroke, recurrence of vascular events, and mortality. Lp-
PLA2 was a good predictor of recurrent stroke risk. Delgado et al. [70] investigated the temporal
profile of Lp-PLA2 mass and activity within the first 24 hours after stroke and found significant
changes in Lp-PLA2 concentrations early after stroke onset. Patients with higher Lp-PLA2 mass
were more likely to be resistant to intravenous t-PA administration with very low early
recanalization rates.
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Lp-PLA2, an inflammatory biomarker, has been described as able to predict risk of first-ever
or recurrent stroke and myocardial infarction [71]. Moreover, Lp-PLA2 may also have a role
in the pathophysiology of cerebrovascular disease, particularly in strokes of atherosclerotic
etiology, since its expression is enhanced in atherosclerotic carotid lesions together with
markers of oxidative damage, inflammation, and instability [72].
Sarlon-Bartoli et al. [73] reported that Lp-PLA2 mass is increased in patients with high-grade
carotid stenosis and unstable plaque and suggest that Lp-PLA2 could be an important bio‐
marker for classifying carotid plaque as vulnerable and predict neurological risk of a carotid
stenosis in asymptomatic subjects. Although these findings have the potential to improve
cerebrovascular disease stratification, correlation with ultrasonic or MRI markers of plaque
instability or the presence of infarction on brain imaging must be performed [74].
Shoamanesh et al. [75] investigated the association between circulating biomarkers of inflam‐
mation including Lp-PLA2 and MRI markers of cerebral small vessel disease in 1,763 stroke-
free Framingham offspring. They observed higher levels of lipoprotein-associated
phospholipase A2 mass in patients with greater white matter hyperintensity volumes and silent
cerebral infarcts. These results could improve stroke risk prognosis.
The accumulating results of numerous studies demonstrate a significant positive association
between Lp-PLA2 levels and incident cardiovascular disease and heart failure. A dissociation
could be noted between mass and activity in terms of risk prediction. Several of the epidemi‐
ology studies have measured only Lp-PLA2 mass (26,30,33,44,47,57,63,65,69), whereas others
measured only enzyme activity (31,50,62,64,67) and a few have measured both in the same
study population (25,27,28, 76). Recently published meta-analysis assessed the 32 prospective
studies of Lp-PLA2 and cardiovascular outcomes. For each standard deviation Lp-PLA2
increase, the relative risks for the primary endpoint of coronary heart disease were 1.10 (1.05–
1.16) and 1.11 (1.07–1.16) for Lp-PLA2 activity and mass, respectively. The relative adjusted
risks for ischemic stroke were 1.08 (0.97–1.20) and 1.14 (1.02–1.27); vascular mortality 1.16
(1.09–1.24) and 1.13 (1.05–1.22); and nonvascular mortality 1.10 (1.04–1.17); and 1.10 (1.03–1.18)
for Lp-PLA2 activity and mass, respectively. The final decision whether to measure the Lp-
PLA2 mass or its enzyme activity may help transition of this biomarker from research to routine
clinical practice.
6. Lp-PLA2 and genetic influences
Several Lp-PLA2 gene polymorphisms and their role in affecting the regulation or production
of LpPLA2 assessed as activity and mass were described; many in small studies and some in
recently published genome-wide association studies. It is known that genetic factors account
for 62% of the variation in Lp-PLA2 activity [76,77].
Although familial factors explain about one-half and one-quarter of the variance in Lp-PLA2
activity and mass, respectively [78,79], few genetic determinants of Lp-PLA2 have been
identified. The first genome-wide association study using data from 6,668 Caucasian subjects
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in population-based Framingham Heart Study identified one locus associated with Lp-PLA2
mass, and four loci associated with Lp-PLA2 activity [80]. Twelve SNPs in the region of
chromosome 6p12.3 near the gene for PLA2G7 were associated with Lp-PLA2 mass at a
genome-wide level of significance. The top hit SNP rs1805017, is a nonsynonymous change
(H92R) within the PLA2G7 gene. It was found that T allele that corresponds to the amino acid
histidine was associated with higher Lp-PLA2 mass. On the other side, four loci achieving
genome-wide significance for association with Lp-PLA2 activity was identified: a) first within
the APOE/APOC1 gene cluster on chromosome 19q13.32 (rs41377151); b) second locus on
chromosome 1p13.3, which includes the genes PSRC1 (rs599839), CELSR2 (rs4970834); c) third
locus within an intron of SCARB1 on chromosome 12q24.31 (rs10846744); d) fourth locus in
ZNF259 gene and BUD13 gene on chromosome 11q23.3 near the apolipoprotein gene cluster
APOA5/APOA4/APOC3/APOA1 (rs12286037, rs11820589). Investigation from Suchindran’s
study was extended by Grallert et al. who made meta-analysis with additional four cohorts
[81]. They performed genome-wide association study as part of the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) Consortium in five population-based
studies with the aim to identify genetic loci related to Lp-PLA2 mass/activity [82]. This study,
in the popoulation of 13,664 subjects, revealed the association of PLA2G7 loci variants with
Lp-PLA2 mass/activity, and genetic variants (APOC1, CELSR2, LDL, ZNF259, SCARB1)
related to low-density lipoprotein cholesterol levels with Lp-PLA2 activity.
Also, Lp-PLA2 mass was associated with SNP rs247616 on chromosome 16 within the choles‐
teryl ester transfer protein gene. The T allele of rs247616 was associated with higher HDL-C
concentration and higher mean Lp-PLA2 mass [83]. The additional value of this study was the
revealed significant association of four polymorphisms (in APOC1, CELSR2, SCARB1,
ZNF259), but not PLA2G7 with coronary heart disease. Large-scale analysis focusing on
variants in PLA2G7 did not identify any SNP that achieved experiment-wide statistical
significance [79].
The most frequently studied SNPs within PLA2G7 are: variants in exon 9 (Val279Phe;
rs45619133), exon 11 (Val379Ala; rs1051931), exon 7 (Ile198Thr, Iso195Thr; rs1805018), and
exon 4 (Arg92His; rs1805017) [84-86].
The V279F SNP was found in subjects of Asian ancestry. The Val279Phe substitution is located
within the catalytical domain of Lp-PLA2 and leads to reduction of enzyme activity in V/F
heterozygous individuals or complete loss of enzymatic activity in homozygous F/F individ‐
uals. The 279F null allele is relatively frequent in Japan, with approximately 25% and 2% of
the population carrying one or two copies. Its prevalence declines toward the West, has
intermediate frequencies in China and Korea, is rare in the Middle East, and almost completely
absent in European populations. The results from the association studies on this V279F variant
and coronary artery disease have thus far been inconclusive. Li et al. [87] in Chinese Han
population, found significant association of V279F and coronary artery disease, indicating that
carrier of F allele increases the risk of coronary artery disease. This result was consistent with
the Yamada et al. [88] study (850 cases/1,684 controls), which found that subjects carrying the
mutant allele are at higher risk of arterial events (MI or stroke), and the Shimokata study (3,085
subjects with coronary artery disease/2,163 controls) [89]. The Jang et al. [90] study in two
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different patient sets (2,890 men diagnosed with CAD before age 60/3,128 male controls and
877 CAD cases/1,230 controls) confirmed that deficiency in Lp-PLA2 activity due to carriage
of PLA2G7 279F allele protects from CAD in Korean men. Nevertheless, in the South Korean
population (532 cases/670 controls) and Chinese study (827 cases/947 controls), V279F variant
results in an unexpectedly opposite outcome [91,92]. Meta-analysis of 14 association studies
focusing on R92H polymorphism in PLA2G7 gene and risk of CHD in 8,280 cases/5,656 controls
indicate 92H allele had probably increased the risk of CHD [92]. The missense polymorphisms
I198T and A379V are identified mainly in Caucasians. A379V variant in which alanine is
substituted by valine is functional. Some studies explored the contribution of A379V to Lp-
PLA2 activity with contradictory results; some found the association of A379V variant with
increased [86,93] and some with decreased Lp-PLA2 activity [94].
There are also different reports about the association between the A379V variant and cardio‐
vascular disease [94-97]. A recent Taiwanese population study reported that subjects carrying
the 379 V allele had increased severity of coronary atherosclerosis [94]; two studies in Cauca‐
sian subjects reported that the 379 V allele was associated with decreased atherosclerosis risk
[93,96]; a large meta-analysis showed that the 379 V allele was associated with Lp-PLA2
activity, but not with cardiovascular risk markers [97]; and another study showed no associ‐
ation [95].
Intriguingly, in the study conducted by Liu and colleagues [94], the outcome was quite
contradictory. They found that in the Chinese Taiwan Han population, A379V variant is
significantly associated with Lp-PLA2 activity and the severity of coronary atherosclerosis.
Recently, a meta-analysis including a total of 12 studies shows that in the populations from
European ancestry, among the 7 SNPs, A379V variant shows the strongest association with
Lp-PLA2 activity; however, no significant correlation is found between PLA2G7 variants and
cardiovascular risk markers, coronary atheroma, or CHD [97].
7. Lp-PLA2 as a therapeutic target
It is well known that lipid-altering medications, including statins, fenofibrate, prescription of
omega-3 fatty acids, for weight loss, have been shown to reduce Lp-PLA2 levels. The degree
of its reduction correlates with the extent of lipid lowering.
Lp-PLA2 was identified as a potential novel target of therapy. The most used therapy targeting
Lp-PLA2 in plasma in advanced stages of clinical investigation is darapladib. Darapladib is a
selective, potent, reversibile, oral inhibitor of lipoprotein-associated phospholipase A2. The
basic idea of applying darapladib is to improve patient outcomes in addition to evidence-based
treatments and potentially reduce cardiovascular and cerebrovascular events by decreasing
cytokines concentrations, stabilizing atherosclerotic plaque, inhibiting macrophage infiltra‐
tion, and thickening of the connective tissue cap.
The first study that showed as a secondary endpoint a change in coronary artery plaque
necrotic core with darapladib after 12 months of treatment was Integrated Biomarkers and
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Imaging Study (IBIS)-2 [98]. It was a multicenter, randomized, double-blind placebo-control‐
led study that included 330 patients with angiographically confirmed coronary artery disease.
Inhibition of Lp-PLA2 with darapladib also prevented necrotic core expansion of coronary
plaque as measured on intravascular ultrasound.
One multicenter, randomized, double-blind placebo-controlled study examined the effects of
darapladib on biomarkers of cardiovascular risk in 959 CAD and CAD-risk equivalent patients
who were previously randomized to atorvastatin 20 mg or 80 mg and then randomized to oral
darapladib 40, 80, 160 mg, or placebo for 12 weeks. Overall dose-dependent inhibition of Lp-
PLA2 activity was sustained over the study period and was present in both atorvastatin dose
groups, at different baseline LDL cholesterol < or ≥70 mg/dl, and high-density lipoprotein
cholesterol HDL-C < or ≥40 mg/dl [99].
The first  study that  examined the effects  of  darapladib on Lp-PLA2  activity in Japanese
dyslipidemic patients with/without the Val279Phe single-nucleotide polymorphism (SNP)
of  the  PLA2G7  gene  showed that  darapladib  produced sustained inhibition  of  Lp-PLA2
activity [100].
Two large-scale studies with hard clinical endpoints were completed: the Stabilization of
Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial, with 15,828
randomized patients, and the Stabilization of Plaques using Darapladib-Thrombolysis In
Myocardial Infarction 52 Trial (SOLID-TIMI 52), with an estimated recruitment of 13,026
patients [101-103].
The SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled, multicenter, and
event-driven trial that determined the clinical benefit of direct inhibition of Lp-PLA2 activity
with darapladib in patients after an acute coronary syndrome (non-ST-elevation or ST-
elevation myocardial infarction). Subjects were randomized to darapladib (160 mg enteric-
coated tablet daily) or matching placebo within 30 days after acute coronary syndrome. The
primary endpoint was the composite of coronary heart disease death, nonfatal myocardial
infarction, or nonfatal stroke, and secondary endpoints were major and total coronary events,
individual components of the primary endpoint, and all-cause mortality. Patients were
followed up for a median of 2.5 years. In patients who experienced an ACS event, direct
inhibition of Lp-PLA2 with darapladib added to optimal medical therapy and initiated within
30 days of hospitalization did not reduce the risk of major coronary events.
The STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY)
trial was a double-blind trial in patients randomized more than one month after a myocardial
infarction to double-blind darapladib (160 mg daily) or placebo (daily). The primary endpoint
was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end‐
points included the components of the primary endpoint as well as major coronary events
(death from coronary heart disease, myocardial infarction, or urgent coronary revasculariza‐
tion for myocardial ischemia) and total coronary events (death from coronary heart disease,
myocardial infarction, hospitalization for unstable angina, or any coronary revascularization).
Patients were followed up for a median of 3.7 years. In patients with stable coronary heart
disease, darapladib did not significantly reduce the risk of the primary composite endpoint of
cardiovascular death, myocardial infarction, or stroke.
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Darapladib is a selective Lp-PLA2 inhibitor that is under investigation for its potential to
stabilize high-risk atherosclerotic plaques and potentially reduce cardiovascular events
[104,105]. A phase 2 clinical trial in 959 patients with CHD or CHD-risk equivalents demon‐
strated that darapladib was effective at producing sustained inhibition of plasma Lp-PLA2
activation in patients on atorvastatin therapy. This study was a post hoc analysis of this phase
2 trial studying high-risk patients with a diagnosis of peripheral arterial disease (PAD). Despite
a more aggressive baseline risk factor profile, darapladib was equally effective at reducing Lp-
PLA2 in patients with and without PAD [106]. Johnson et al. [107] assessed the effects of
darapladib on both plasma and plaque Lp-PLA2 activity in patients undergoing elective carotid
endarterectomy randomized to darapladib 40 mg (n = 34), 80 mg (n = 34), or placebo (n = 34)
for 14 days. Patients were followed by carotid endarterectomy 24 hours after the last dose of
study medication. Darapladib reduced plasma and plaque Lp-PLA2 activity compared with
placebo.
8. Conclusion
Within the last decade, a broad range of biomarkers associated with an increased risk for death
and cardiovascular/cerebrovascular endpoints have been identified. Epidemiological studies
clearly indicated that Lp-PLA2 has the potential to become a clinically useful biomarker
because it promotes independent information in the diagnosis, and especially cardiovascular/
cerebrovascular risk stratification. In the future, we can expect new drugs (new Lp-PLA2
inhibitors) that will affect patient’s management, and assessing the effect of Lp-PLA2 inhibition
on cardiovascular endpoints can provide definitive answers.
However, further clinical validation in well-designed observational and interventional studies
is needed before these recommendations can be properly evaluated in order to include them
in the clinical diagnostic algorithms.
Currently, Lp-PLA2 measurement has only been reserved to patients with moderate and high
cardiovascular risk, rather than healthy population or low-risk patients, since the values of Lp-
PLA2 in these population groups are insignificant. Also, the evaluation of Lp-PLA2 in combi‐
nation with noninvasive imaging could be expected. The formation of best-case model from
Lp-PLA2 and other biomarkers can yield the best patient stratification algorithm. The next step
could be cost-effectiveness analysis of more accurate risk stratification with biomarker testing.
Future studies need to focus on exploring the potential of this biomarker and evaluating the
effects of Lp-PLA2 inhibition on human populations.
The final decision on which test to use for Lp-PLA2 determination, test based on mass or activity
of Lp-PLA2, together with the development of commercially available automated, robust,
valid, high throughput, cost-effective test capable of increasing agility and reducing the
analytical imprecision can be adopted routinely in clinical practice for better risk stratification
and therapeutic choice in patients with cardiovascular/cerebrovascular disease.
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